

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 2 | — | — | — | 3 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 2 | — | — | — | 3 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 2 | — | — | — | 2 |
| Drug common name | REMTOLUMAB |
| INN | remtolumab |
| Description | Remtolumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tumor necrosis factor and interleukin-17A. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297863 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 1V8WRH3RVX (ChemIDplus, GSRS) |
